Introduction {#S1}
============

Degenerative disc disease (DDD) is a major origin of low back pain, which is the leading cause of activity limitation and work absence and results in a high economic burden ([@B51]). In the United States, the yearly costs related to back pain are around 100--200 billion USD ([@B29]). DDD is defined as symptomatic intervertebral disc (IVD) degeneration, whereby nociception is thought to be linked to increased levels of proinflammatory cytokines within the tissue, including IL-1β, TNF-α, IL-6, IL-8, and IFN-γ ([@B76]; [@B27]). While current treatment options for DDD, including oral analgesics and surgery, solely aim to reduce the symptoms, researchers have made extensive efforts over the past decade to develop novel therapeutic approaches that target the underlying pathophysiological mechanisms, i.e., degeneration, inflammation, and enhanced apoptosis ([@B18]; [@B63]). A wide range of approaches has been tested which are described in detail elsewhere ([@B34]; [@B60]; [@B11]; [@B23]; [@B41]), ranging from autologous disc cell therapy, growth factors, biologics, gene transfection, and biomaterials to CRISPR/Cas9 genome engineering, as well as the use of mesenchymal stem cells (MSCs). However, none of these concepts have been successfully incorporated yet into daily clinical practice.

As in numerous other fields, great hopes were pinned on MSCs for the treatment of DDD due to their regenerative and anti-inflammatory potential that would allow simultaneously targeting all primary pathological drivers ([@B68]; [@B41]). Furthermore, MSCs have excellent proliferation characteristics and good accessibility from either bone marrow or fat tissue. However, numerous studies demonstrated that the success of MSC-based treatments is limited due to the harsh microenvironment of the degenerated IVD that hampers their survival and functionality ([@B75]; [@B24]). Although various techniques have recently been developed that may promote MSC survival and functionality in the IVD, such as priming and pre-differentiation of MSCs, selection of specific MSC subpopulations, and rewiring of the genetic circuits of MSCs by CRISPR ([@B34]; [@B41]), there has been an increasing shift toward cell-free, yet MSC-related therapies to avoid the aforementioned challenges. While early studies investigated the regenerative and anti-inflammatory potential of MSC-conditioned media in IVD cells ([@B43]; [@B62]), extracellular vesicles (EVs) have increasingly moved into this area of research. EVs are lipid membrane particles that carry proteins, lipids, DNA, and various types of RNA, and function as nanocarriers with relevance in intercellular communication. As recently summarized by [@B30], EVs may be the primary or possibly sole driver of MSC-driven regeneration and could thus represent a potential alternative treatment for DDD. Although very few studies thus far have compared the potential of conditioned media in triggering cell responses to EVs isolated from the same conditioned medium, first evidence suggests a comparable (astrocytes on motor neurons; notochordal cells on chondrocyte-like IVD cells) ([@B2]; [@B69]) or enhanced beneficial effect (umbilical cord MSCs on T cells) ([@B49]) of EVs. However, conclusions are challenging to draw as dose-effects are difficult to control for in these experimental set-ups.

This mini-review will briefly summarize both established and more advanced techniques for the collection and size-sorting of EVs before presenting evidence on the content and function of MSC-derived EVs on cells from the inner region of the IVD, the nucleus pulposus (NP). Furthermore, knowledge on the characterization of EVs released from IVD cells are briefly summarized and future areas of research are highlighted.

EV Terminology {#S2}
==============

With a rapid increase in EV-related research over the past years, one of the major limitations is the use of heterogeneous, often field-specific, nomenclature. In IVD research, the term exosome is commonly used, whereas the terms microvesicles, apoptotic bodies, and microparticles are less common. Importantly, the rather historical classification of these particles according to size is outdated as recent studies have shown significant overlap in particle subtype sizes ([@B32]; [@B66]). Knowledge of particle biogenesis is necessary to accurately identify specific subtypes ([@B20]; [@B33]). Ongoing research may be able to provide specific markers for the various particle subtypes and thus allow accurate classification in the future. Hence, according to the recommendation of the International Society of Extracellular Vesicles (ISEV) and the Minimal Information for Studies of Extracellular Vesicles, 2018 (MISEV2018) ([@B65]), we will use the name EVs in this mini-review as the generic term for particles naturally released from cells that are delimited by a lipid bilayer and cannot replicate.

Collection and Purification of EVs {#S3}
==================================

In order to study the biological roles and potential applications of EVs, the first step is to reliably and efficiently isolate them from biological fluids and conditioned media. Ideal isolation methods purify intact EVs with preserved biological function and without contamination by proteins or non-EV particles. Over the past years, many techniques have been developed to isolate EVs based on properties such as size, density, and surface proteins, including ultracentrifugation, ultrafiltration, precipitation, and affinity-based techniques.

The most commonly employed technique was first described by [@B64] and is known as differential ultracentrifugation, which refers to a stepwise increase of centrifugal forces that results in sequential pelleting of different size of particles. However, differential ultracentrifugation is a time consuming, expensive process with co-isolation of contaminants and low yields. To increase the purity of the EV sample, differential centrifugation is often coupled with other techniques such as ultrafiltration through 0.2, 0.4, and 0.8 um filters, yet with negative impact on the overall EV yield and the potential for deformation and damage of EVs ([@B78]). Due to aforementioned limitations and complications, a number of research efforts have aimed to develop more reproducible, reliable, and standardized methods that avoid contamination and damage to EVs, including size exclusion chromatography ([@B13]; [@B40]; [@B19]), filtration ([@B22]; [@B74]; [@B14]), immuno-affinity based approaches ([@B28]), and microfluidic techniques ([@B38]; [@B80]).

In the IVD field, the majority of studies have used differential centrifugation protocols. Some modified these protocols by adding a filtration step between the centrifugation steps, while others replaced the ultracentrifugation step by the use of commercially available precipitation-based kits (e.g., "Total Exosome Isolation Reagent"). Precipitation-based techniques have a high yield but tend to suffer from low purity. Two IVD studies showed fractionation of conditioned media by ultrafiltration through membranes with different molecular weight cut-offs (MWCO), yielding spherical species with a size range of 50--100 nm. Overall, techniques currently used in IVD research for collection and purification of EVs are widespread and common, but could be replaced by recent technical advancements. By incorporating newer approaches and more sophisticated techniques such as tangential flow filtration (TFF) and size exclusion chromatography ([@B12]; [@B48]; [@B14]), reliability and reproducibility of IVD studies could likely be further improved.

Production, Stability and Storage of EVs {#S4}
========================================

The lipid bilayer membrane of EVs plays an important role in their stability by protecting their bioactive cargo against degradation ([@B26]). In order to fully utilize EVs for clinical applications, a better understanding of the effect of pH, temperature and storage conditions on their stability is required. Different storage techniques such as cryopreservation ([@B4]), lyophilization ([@B35]), and spray drying have been reported ([@B36]). Storage at −80°C has been recognized as the most promising method for long-term preservation of EV properties and functions. However, it is important to note that studying their stability of EVs can be affected by their cells of origin, purification technique and characterization method ([@B25]). Interestingly, slightly acidic conditions like those of the IVD have been shown to both increase the release as well as uptake of EVs, especially in cancer cells ([@B53]; [@B56]; [@B10]).

Characterization of EVs {#S5}
=======================

The presence of EVs in a purified sample should be confirmed by multiple methods. Western blot (WB) has been employed to characterize the isolated samples by evaluating the presence of EV-enriched markers and the absence of negative markers. Alix, TSG101 and surface associated markers such as Tetraspanins (CD9, CD63, and CD81) have been used as positive markers for EVs ([@B47]; [@B9]), while proteins associated with cell compartments other than endosome or plasma membrane such as Calnexin (endoplasmic reticulum) and GM130 (Golgi) have been used as negative markers ([@B42]; [@B70]; [@B73]). In addition to protein composition, Transmission electron microscopy (TEM) and Nanoparticle Tracking analysis (NTA) are the two most commonly used technique for studying the morphology (cup-shaped with double layer membrane structures), size and concentration of EVs ([@B9]; [@B39]). In the future, isolation of different subpopulations of EVs based on their biogenesis (exosomes, microvesicles and apoptotic bodies) and size (small, medium and large) are crucial for identifying their therapeutic potential. Moreover, high-resolution flow cytometry can be applied for single EV analysis which provides valuable information regarding size, concentration and identifying the phenotype subsets of EVs.

Delivery of EVs {#S6}
===============

Although systemic delivery of EVs is generally considered the easiest approach, biodistribution patterns indicate accumulation in the liver, spleen, and lungs ([@B15]). Especially when taking the avascular nature of the IVD into account, local delivery has to be regarded as the prime route of administration for future clinical applications. Whether or not EVs should be embedded into biomaterial-based carriers will, however, require further investigation, as does the optimal dose of EVs.

While defining optimal doses has been a crucial aspect in MSC-based IVD therapies due to the limited nutritional supply within the tissue ([@B41]), EV dosing will likely be less critical. However, difficulties to obtain large amounts of EVs, combined with the associated high costs, will nonetheless require determining the minimal EV concentration that provides adequate therapeutic effects.

Extracellular vesicles have been shown to bind to ECM-proteins such as fibronectin and collagen type I ([@B50]), which may be sufficient to ensure their captivity within the IVD tissue, despite daily mechanical loading and consequential fluid flow out of the tissue. Should *in vivo* tracking studies of EVs (labeled e.g., by superparamagnetic iron oxide nanoparticles, radioisotopes or fluorescent dyes) ([@B15]), however, demonstrate high loss of EVs from the IVD, biomaterial-based delivery approaches, similar to those used for MSCs themselves ([@B7]), may become useful. In fact, a previous study on wound healing has demonstrated that the use of a chitosan/silk hydrogel provided sustained release of EVs while preserving their function ([@B59]).

EVs From Ivd Cells: Function and Content {#S7}
========================================

Only few studies have thus far been conducted on IVD-derived EVs, although they most certainly play a crucial role during IVD health and disease. In fact, researchers in other fields have become increasingly interested in the analysis of EVs from resident cells, with the hope to identify specific disease biomarkers ([@B8]). With the current interest in biomarkers for DDD ([@B31]; [@B6]), research in this context will certainly arise in the short- to mid-term future. Nonetheless, past research has been limited to the function and content of IVD-derived EVs ([Figure 1](#F1){ref-type="fig"}), with a focus on miRNAs as these small non-coding RNA molecules are being extensively investigated for their therapeutic potential in other fields. [@B52] provide a comprehensive overview of EV-miRNAs with biological relevance in a broad range of application areas, including miR-let-7b, miR-let-7c, miR-17-92, miR-21, miR-23b, miR-125a, miR-133b, miR-146a, miR-221, miR-223, and miR-1587.

![Current knowledge on the function and content of (1) NP-derived EVs and of (2) MSC-derived EVs for the treatment of NP cells. No data exists yet on annulus fibrosus (AF) cells, the more fibroblast-like cells from the outer area of the IVD.](fbioe-08-00311-g001){#F1}

[@B47] demonstrated that NP cells in a rodent herniation model produce EVs containing miR-223. Importantly, miR-223 was furthermore found to decrease the C-fiber response in the dorsal horn neurons and to inhibit the nociceptive spinal signaling compared to PBS controls, hence indicating its protective role during IVD herniation and chronic lumbar radicular pain. Interestingly, EV-derived miR-223 has also been shown to downregulate inflammation following cardiac surgery with cardiopulmonary bypass ([@B54]) and this anti-inflammatory function of miR-223 (through modulation of the NF-kB pathway) was already confirmed in NP cells ([@B71]). However, Wang et al. analyzed the anti-inflammatory role of miR-233 in the IVD in miR-233-overexpressing NP cells (and did not investigate miR-233 in released EVs).

Concerning function of IVD-derived EVs, data on notochordal NP cells and chondrocyte-like NP cells have been published. Notochordal cells are a developmental cell type in the NP that, at least in humans and some other species, gets increasingly replaced by chondrocyte-like IVD cells over the course of life; the reduction in notochordal cell number is believed to be associated with the onset of IVD degeneration ([@B57]). Notochordal cell-derived EVs increased DNA and glycosaminoglycan content in human NP cell micro-aggregates compared to untreated control medium, although the underlying mechanism or the associated EV content was not analyzed in this study by the Tryfonidou Lab ([@B2]). EVs harvested from human NP cells derived from patients with lumbar degenerative disease were able to promote MSC migration and differentiation into an NP-like phenotype ([@B42]) through the Notch1 pathway ([@B37]), although the EV content responsible for this action (e.g., specific miRNAs) remains unknown at this time. However, a delicate interplay between different miRNAs and components of Notch signaling pathway has been identified in cancer, pointing toward miR-146a, miR-19, miR-100, miR-21, miR-181a-1/b-1, miR-375, and miR-483-5p as potentially interesting candidates for further investigation in the IVD field ([@B44]).

EVs From Mscs: Effects on Ivd Cells and Content {#S8}
===============================================

Ample evidence exists from a variety of fields that MSC-derived EVs have therapeutic effects ([@B52]), including musculoskeletal applications ([@B1]). To ensure reproducibility of results and facilitate the exchange of data among investigators, it is essential that researchers characterize their MSCs according to the guidelines of the International Society for Cellular Therapy (plastic-adherence; lineage differentiation potential; expression of CD105, CD73 and CD90; lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and HLA-DR) ([@B17]).

As the success of MSC cell therapies for IVD diseases has been hampered due to the restricted survival and functionality of the cells in the harsh IVD microenvironment ([@B75]; [@B24]), the use of cell-free therapeutic applications may circumvent many of the past translation obstacles, especially if they could halt or reverse the hallmarks of DDD ([Figure 1](#F1){ref-type="fig"}). However, it has to be noted that no studies have thus far directly investigated whether the harsh microenvironment of the IVD might affect EV functionality. [@B10] investigated the stability of EVs derived from HEK 293T cells at pH 4 and pH 7 and found a concentration loss at pH 4, which, however, is too acidic even for the degenerated IVD. On the other hand, acidic microenvironments may actually increase the uptake of EVs ([@B53]; [@B56]; [@B10]).

Preventing Apoptosis and Promoting Proliferation {#S8.SS1}
------------------------------------------------

Cellular loss, predominantly through apoptosis, is an evident hallmark and is thought to play a crucial role in the degenerative processes of the IVD. Therefore, minimizing cell death has been discussed as an auspicious therapeutic strategy for IVD degeneration ([@B16]). MSC-derived EVs have proven to be effective modulators of NP cell survival and apoptosis, whereby the effect seems to be mediated through activation of the pro-survival PI3K-Akt pathway and ERK pathway, possibly through miR-21 ([@B9]; [@B39]). The apoptosis-reducing effect of EVs via PI3K-Akt and ERK has been confirmed in chondrocytes ([@B81]), while the role of miR-21 was confirmed by miR-21 enriched EVs in cardiomyocytes *in vitro* and during myocardial infarction *in vivo* ([@B61]). In the IVD, the inhibition of cell apoptosis through EVs, potentially in combination with other unidentified mechanisms, decelerated progression of IVD degeneration in a rat tail degeneration model based on the injection of advanced glycation end products ([@B39]).

Aside from attenuating apoptosis, MSC-derived EVs also have the potential to promote proliferation of NP cells ([@B42]). The mechanisms thereof are thus far unidentified, although AKT and ERK signaling may likely be involved ([@B55]).

Inducing ECM Synthesis {#S8.SS2}
----------------------

A loss of proteoglycans and collagen-II in the NP is one of the most prominent features of IVD degeneration and DDD, clearly visible through MR-based imaging as a black disc. Therefore, regenerative IVD therapies typically focus on promoting the synthesis of IVD-typical extracellular matrix (ECM) proteins by various means, including MSCs and MSC-derived EVs. In fact, [@B42] provided compelling evidence that MSC-derived EVs can induce a healthier ECM production in NP cells, as indicated by enhanced gene expression and synthesis of aggrecan, SOX-9 and collagen-II. The efficacy of MSC-derived EVs has also been demonstrated in numerous cartilage repair/regeneration studies ([@B83]; [@B5]; [@B45]; [@B67]), whereby these effects may be mediated through miR-92a-3p and WNT5A ([@B45]). Evidently, more studies will be needed to confirm the capacity of EVs to promote IVD health and homeostasis, but also to identify the EV content responsible for the beneficial effects.

Modulating Inflammation {#S8.SS3}
-----------------------

As chronic inflammation in the IVD arising from resident cells (and in the case of structural failure of the tissue also from invading immune cells) is associated with back pain development ([@B76]; [@B27]), many researchers consider the modulation of inflammation as therapeutically more relevant and achievable than inducing full regeneration. Following this strategy, [@B77] tested whether MSC-derived EVs can reduce H~2~O~2~-induced inflammation in NP cells. Results of this study provide compelling evidence for anti-inflammatory properties of EVs via modulation of the NLRP3 inflammasome and through restoration of damaged mitochondria ([@B77]). Although not yet investigated in the IVD, NLRP3 inflammasome activity is known to be controlled by miR-223 ([@B3]). Importantly, the positive effects of EVs were not restricted to *in vitro* conditions but could also be replicated in a rabbit IVD degeneration model ([@B77]). Whether MSC-derived EVs may also affect the phenotype of invaded macrophages in the IVD and thus cause a shift from an inflammatory M1 toward a regenerative M2 phenotype is currently unclear, albeit initial data in that respect could be collected in skin ([@B21]).

To further improve the outcome of EV therapy, MSCs can be modified to produce EVs with enhanced or reduced content of certain components with biological activity, such as specific miRNAs. With an increasing understanding of the role of certain miRNAs in IVD health and disease ([@B82]), EV therapy may thus be optimized in a tissue- and disease-specific manner. In cartilage for example, miRNA-140 has been identified to regulate tissue homeostasis. Transduction of MSCs with lentiviral miR-140-5p resulted in EVs that increased chondrocyte proliferation and promoted cartilage regeneration compared to the control (= negative control oligonucleotides/vector group) ([@B72]). Clearly, EVs from modified MSCs have a significant potential as future therapeutic strategies. Similar approaches can be envisioned in the IVD field, targeting for example miR-210, which was shown to inhibit NP cell apoptosis ([@B79]), or potentially also miR-483, which is downregulated during intervertebral disc disease ([@B58]).

Despite the promise that initial studies on MSC-derived EVs have sparked, one of the remaining challenges may be the limited distribution of EVs within the IVD due to the densely packed collagen and proteoglycan-rich ECM. However, this dense ECM may also help to retain EVs within the IVD following intradiscal injections. Mathematical models should be employed in the future to further investigate this question and to determine whether specific EV sizes or EV membrane compositions would be best suited for IVD applications. However, these parameters will not only affect tissue retention and distribution, but also biological activity, and both aspects will need to be considered ([@B46]).

Discussion and Outlook {#S9}
======================

First research results on MSC-derived EVs for the treatment of DDD clearly demonstrate their therapeutic potential by promoting regeneration and proliferation and reducing inflammation and apoptosis in the IVD, although the exact mechanisms of action are not yet fully elucidated.

Ample studies in the past have investigated MSC-based therapies for the IVD, leading to increasing knowledge on the bidirectional crosstalk between MSCs and IVD cells. However, MSC cell therapy for the IVD is hampered by the harsh tissue microenvironment; furthermore, cell therapies face safety concerns and thus approval challenges. Although few studies have investigated the effect of e.g., acidic pH on EV stability, it is conceivable that the negative effects that the harsh IVD microenvironment has on MSCs themselves is not relevant for EV-based therapies. In fact, first studies demonstrated a possible increase of cellular uptake of EVs under IVD like pH conditions. Investigating the effect of the harsh IVD microenvironment on EVs is thus an important topic for future investigation.

Despite these advantages of EVs compared to MSC cell therapy, a major limitation lies in their low yields. However, technical advancements related to fast expansion of MSCs as well as enhanced release of EVs that can be induced by commercially available media and additives in combination with new purification strategies will likely help to overcome this restraining factor.

It has become increasingly evident that exposure of MSCs to biophysical and/or biochemical cues may help to further improve the clinical outcome. Therefore, future investigations should aim to identify which signals can enhance the regenerative and/or the anti-inflammatory capacity of EVs, specifically on IVD cells. Alternatively, studies may identify certain subpopulations of EVs that have increased therapeutic properties and/or enhanced tissue retention, based on size characteristics or membrane composition, for example. The use of a biomaterial-based carrier for the *in vivo* delivery of EVs may further enhance the therapeutic benefits through improved captivity within the IVD tissue, sustained release and/or preservation of function.

With the development of novel techniques for the production, collection and delivery of EVs or EV subpopulations, ample possibilities for optimization of EV therapies may arise. However, a better understanding and subsequent optimization of the effects that temperature and storage conditions have on EV stability will be required to promote successful translation into the clinical setting.
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